Lilly’s lepodisiran, given at the highest dose, reduced a heart disease-linked protein to undetectable levels for 48 weeks, according to the study.
Read More
The Indianapolis-based drug company is ramping up manufacturing capacity to avoid possible shortages and to meet potentially huge demand in a nation where more than 40% of adults are classified as obese.
Read More
The drugmaker accused 11 companies of importing products that they say contain tirzepatide, the active ingredient in Mounjaro, while falsely implying that their products are associated with Eli Lilly or approved by the FDA.
Read More
Eli Lilly and Co. just hit another bump in the road in its quest to push deeper into treatments for skin diseases, the third setback this year for the Indianapolis-based drugmaker from the U.S Food and Drug Administration.
Read More
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
The extension comes amid pushback from several investors, including Point’s largest institutional stock holder.
The announcement represents the company’s latest move to meet the soaring demand for its medicines for diabetes and weight loss.
The research is the first to document that an obesity medication can not only pare pounds, but also safely prevent a heart attack, stroke or a heart-related death in people who already have heart disease—but not diabetes.
Eli Lilly and Co.’s hot-selling diabetes drug, Mounjaro, will now be sold for a second use, chronic weight management, using a separate brand name, Zepbound.
Excluding nonrecurring items, the Indianapolis-based drugmaker posted adjusted earnings of 10 cents a share, beating Zacks consensus estimate of a loss of 11 cents a share.
Eli Lilly and Co. will study its blockbuster diabetes drug Mounjaro in combination with an experimental muscle-loss treatment as it searches for ways to help patients maintain muscle while losing weight.
The technology hub designation makes Indiana eligible to compete against 30 other designated hubs in hopes of landing up to $70 million in federal funding to implement its program.
According to the petition Courtney Anguiano knowingly conspired with seven other people to submit 189 false and fraudulent post-transaction reimbursement requests under three different Eli Lilly and Co. savings card programs.
Top executives and directors of Indianapolis-based Point Biopharma Global Inc. could rake in an eye-popping $212 million from their deal to sell the company to drugmaker Eli Lilly and Co.
The results, which were also presented Sunday at a medical conference, confirm that the drug made by Eli Lilly and Co. has the potential to be one of the most powerful medical treatments for obesity to date, outside experts said.
Eli Lilly and Co. is paying Indianapolis-based startup Point Biopharma $12.50 a share, an 85% premium over the company’s closing price on Monday of $6.68 a share.
The decision represents a rare case of a judge overturning a jury verdict and is a major win for Lilly, which argued strenuously that its Emgality drug is substantially different than Anjovy, a drug sold by competitor Teva Pharmaceuticals.
The solar structures are designed to help generate power for the company and reduce its carbon footprint.
Lilly is suing medical spas, wellness centers and compounding pharmacies in various U.S. states that sell unapproved versions of its blockbuster diabetes drug, which is frequently used off-label for weight loss.
The group hopes to improve civic education in a state that ranks among the bottom nationally when it comes to voter registration and turnout.
The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.
